Point72 (DIFC)’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
Other funds holding ITOS
RCM
BI
MAM
TCM
6CM
MB
Point72 (DIFC)'s ITOS Position: Q1 2025 in Review
Point72 (DIFC) sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 8,794 shares — an estimated $67.5K sold.
Point72 (DIFC) first reported a position in ITOS in Q1 2024 and held it in 3 quarters. The position peaked at $67.5K in Q4 2024. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.
- Point72 (DIFC) reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
- Point72 (DIFC) sold 8,794 iTeos Therapeutics shares in Q1 2025, an estimated $67.5K.
- Point72 (DIFC) first reported a position in iTeos Therapeutics in Q1 2024 and held it in 3 quarters.
- Point72 (DIFC)'s iTeos Therapeutics position peaked at $67.5K in Q4 2024.
- 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.
Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.